You have free access to this content

Cancer

Cover image for Vol. 117 Issue 21

1 November 2011

Volume 117, Issue 21

Pages 4807–5021

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      Utilization and expense of adjuvant cancer therapies following radical prostatectomy (pages 4810–4811)

      Benjamin Spencer

      Article first published online: 11 APR 2011 | DOI: 10.1002/cncr.26008

      Several randomized trials and a treatment guideline favor the use of adjuvant therapy for patients with adverse pathological features identified at radical prostatectomy. This study describes the variation in patterns of utilization and costs associated with these therapies.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      Current trends and emerging future of indocyanine green usage in surgery and oncology : A literature review (pages 4812–4822)

      Karol Polom, Dawid Murawa, Young-soo Rho, Piotr Nowaczyk, Michael Hünerbein and Pawel Murawa

      Article first published online: 11 APR 2011 | DOI: 10.1002/cncr.26087

      Indocyanine green (ICG) fluorophore has had a significant impact in various fields of surgical oncology. In this review, the authors discuss its promising potential, in addition to assessing several challenges and limitations in the context of specific surgical procedures and ICG as a whole.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. Disease Site

      Gastrointestinal Disease
      You have free access to this content
      Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy (pages 4823–4833)

      Akihiro Suzuki, Lianchun Xiao, Yuki Hayashi, Homer A. Macapinlac, James Welsh, Steven H. Lin, Jeffrey H. Lee, Manoop S. Bhutani, Dipen M. Maru, Wayne L. Hofstetter, Stephen G. Swisher and Jaffer A. Ajani

      Article first published online: 31 MAR 2011 | DOI: 10.1002/cncr.26122

      In 209 esophageal cancer patients who had bimodality therapy, of whom 180 had baseline positron emission tomography, higher initial standardized uptake value was associated with longer tumors (P = .0001), higher T-stage status (P < .0001), positive N-stage status (P = .0001), higher overall stage (P < .0001), lack of clinical complete response (P = .0002), and squamous cell histology (P < .0001). Clinical complete response after chemoradiation was associated with better overall survival.

    2. You have free access to this content
      Neurogenesis in colorectal cancer is a marker of aggressive tumor behavior and poor outcomes (pages 4834–4845)

      Daniel Albo, Catherine L. Akay, Christy L. Marshall, Jonathan A. Wilks, Gordana Verstovsek, Hao Liu, Neeti Agarwal, David H. Berger and Gustavo E. Ayala

      Article first published online: 8 APR 2011 | DOI: 10.1002/cncr.26117

      The results from this study provided evidence of neurogenesis in vitro and in vivo; specifically, the authors report the phenomenon of neurogenesis in colorectal cancer and its association with aggressive stages of colorectal cancer. Neurogenesis was indicative of poor survival and recurrence and was an independent prognostic factor for poor outcomes in patients with colorectal cancer. The authors concluded that neurogenesis offers the potential for better therapy stratification of patients with lymph node-negative colorectal cancer.

    3. Genitourinary Disease
      You have free access to this content
      Utilization and expense of adjuvant cancer therapies following radical prostatectomy (pages 4846–4854)

      Stephen B. Williams, Xiangmei Gu, Stuart R. Lipsitz, Paul L. Nguyen, Toni K. Choueiri and Jim C. Hu

      Article first published online: 1 MAR 2011 | DOI: 10.1002/cncr.26012

      Men treated by high-volume surgeons were less likely to receive secondary therapies. Regional variation, high-risk disease characteristics, and positive surgical margins were associated with increased receipt of secondary therapies, which increased health expenditures by 2- to 3-fold when radiotherapy was administered.

    4. You have free access to this content
      Reverse stage shift at a tertiary care center : Escalating risk in men undergoing radical prostatectomy (pages 4855–4860)

      Jonathan L. Silberstein, Andrew J. Vickers, Nicholas E. Power, Samson W. Fine, Peter T. Scardino, James A. Eastham and Vincent P. Laudone

      Article first published online: 11 APR 2011 | DOI: 10.1002/cncr.26132

      At a large tertiary care center, the authors observed increasing clinical and pathologic features in men with prostate cancer who elected to undergo radical prostatectomy despite an increased use of minimally invasive techniques. This reverse stage shift may have been caused in part by an increased use of active surveillance.

    5. Hematologic Malignancies
      You have free access to this content
      Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia (pages 4831–4868)

      Meir Wetzler, Chris Andrews, Laurie A. Ford, Sheila Tighe, Maurice Barcos, Sheila N. J. Sait, AnneMarie W. Block, Norma J. Nowak, Maria R. Baer, Eunice S. Wang and Heinz Baumann

      Article first published online: 31 MAR 2011 | DOI: 10.1002/cncr.26097

      A phase 1 clinical trial with arsenic trioxide (ATO), high-dose cytarabine, and idarubicin was designed to down-regulate signal transducer and activator of transcription 3 activity in vivo in patients with acute myeloid leukemia. The maximum tolerated dose of ATO was 0.5 mg/kg. The favorable outcome of patients on this protocol suggested a potential benefit of the addition of ATO to upfront leukemia therapy.

    6. You have free access to this content
      Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement : Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial (pages 4869–4877)

      Ruben A. Mesa, Hagop Kantarjian, Ayalew Tefferi, Amylou Dueck, Richard Levy, Kris Vaddi, Susan Erickson-Viitanen, Deborah A. Thomas, Jorge Cortes, Gautam Borthakur, Animesh D. Pardanani, Zeev Estrov and Srdan Verstovsek

      Article first published online: 8 APR 2011 | DOI: 10.1002/cncr.26129

      This article highlights the ability of the Myelofibrosis Symptom Assessment Form to capture myelofibrosis symptoms at baseline and serially during a clinical trial. Results of the Myelofibrosis Symptom Assessment Form used in the JAK2 inhibitor (INCB018424) trial in 87 patients demonstrated the correlation between symptomatic response and objective disease improvements.

    7. Hepatobiliary Disease
      You have free access to this content
      Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection (pages 4878–4889)

      Tong Ding, Jing Xu, Ying Zhang, Rong-Ping Guo, Wen-Chao Wu, Shao-Dan Zhang, Chao-Nan Qian and Limin Zheng

      Article first published online: 8 APR 2011 | DOI: 10.1002/cncr.26137

      The presence of endothelium-coated tumor clusters, which were associated with micrometastasis and early relapse after resection, is an efficient and independent predictor of a poor prognosis in patients with hepatocellular carcinoma (HCC), and may serve as a potential novel target for the prevention and treatment of HCC metastasis.

    8. You have free access to this content
      Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma (pages 4890–4904)

      Shohei Komatsu, Takumi Fukumoto, Yusuke Demizu, Daisuke Miyawaki, Kazuki Terashima, Ryohei Sasaki, Yuichi Hori, Yoshio Hishikawa, Yonson Ku and Masao Murakami

      Article first published online: 14 APR 2011 | DOI: 10.1002/cncr.26134

      In this study, favorable clinical treatment results were demonstrated with both proton therapy and carbon ion therapy for hepatocellular carcinoma (HCC). Both therapies exhibited great advantages in treating HCC, a condition for which other local therapies are contraindicated. Thus, both proton therapy and carbon ion therapy may be innovative alternatives to conventional local therapies for HCC.

    9. Neuro-Oncology
      You have free access to this content
      A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas (pages 4905–4915)

      William T. Couldwell, Amy A. Surnock, Alfonso J. Tobia, Bernard E. Cabana, Charles B. Stillerman, Peter A. Forsyth, Alan J. Appley, Alexander M. Spence, David R. Hinton and Thomas C. Chen

      Article first published online: 31 MAR 2011 | DOI: 10.1002/cncr.26123

      Hypericin is a potent inhibitor of glioma growth in a dose-related manner in vitro and has exhibited marked inhibition of growth, motility, and invasion in the low-micromolar concentration range. The results from this phase 1/2 open-label, sequential dose escalation/de-escalation tolerance study of synthetic oral hypericin in patients with recurrent malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) indicated that it is well tolerated and exhibits efficacy in this difficult patient group, suggesting that further trials of hypericin as adjuvant therapy for patients with malignant glioma are warranted.

    10. Soft Tissue and Bone Sarcoma
      You have free access to this content
      Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors : Current overall survival after primary tumor resection (pages 4916–4924)

      Piotr Rutkowski, Agnieszka Wozniak, Maria Dębiec-Rychter, Michał Kąkol, Wirginiusz Dziewirski, Marcin Zdzienicki, Konrad Ptaszynski, Monika Jurkowska, Janusz Limon and Janusz A. Siedlecki

      Article first published online: 31 MAR 2011 | DOI: 10.1002/cncr.26079

      This study of 640 primary, resectable gastrointestinal stromal tumors (GISTs) confirmed the reliability of the American Joint Committee on Cancer risk classification in terms of disease-free and overall survival. Patients who had primary GISTs originating from the stomach had a better prognosis compared with patients who had GISTs in other locations; however, in both groups, primary tumor size and mitotic activity were the most important prognostic factors for disease-free survival.

    11. You have free access to this content
      Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma (pages 4925–4938)

      Jilong Yang, Da Yang, Yan Sun, Baocun Sun, Guowen Wang, Jonathan C. Trent, Dejka M. Araujo, Kexin Chen and Wei Zhang

      Article first published online: 14 APR 2011 | DOI: 10.1002/cncr.26116

      By using integrated microarray-based comparative genomic hybridization (aCGH), fluorescent in situ hybridization (FISH), and immunohistochemistry analyses, the authors identified genetic amplification of vascular endothelial growth factor (VEGF) pathway genes and validated VEGFA gene amplification in human osteosarcoma, either focally or in larger fragments.

    12. You have free access to this content
      Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor (pages 4939–4947)

      Min S. Park, Shreyaskumar R. Patel, Joseph A. Ludwig, Jonathan C. Trent, Charles A. Conrad, Alexander J. Lazar, Wei-Lien Wang, Piyaporn Boonsirikamchai, Haesun Choi, Xuemei Wang, Robert S. Benjamin and Dejka M. Araujo

      Article first published online: 8 APR 2011 | DOI: 10.1002/cncr.26098

      For patients with recurrent and/or metastatic hemangiopericytoma/solitary fibrous tumors, combination therapy with temozolomide and bevacizumab showed encouraging results. This anti–vascular endothelial growth factor treatment strategy warrants further evaluation in future clinical trials.

    13. Discipline

      Epidemiology
      You have free access to this content
      Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival : The Seattle Colon Cancer Family Registry (pages 4948–4957)

      Amanda I. Phipps, John Baron and Polly A. Newcomb

      Article first published online: 14 APR 2011 | DOI: 10.1002/cncr.26114

      In a population-based cohort of individuals with incident colorectal cancer, the authors evaluated the association between smoking history, recent alcohol consumption, and disease survival according to sex, tumor subsite (proximal, distal, rectal), and microsatellite instability status. Mortality risk was significantly higher in smokers than in never-smokers, particularly when analyses were restricted to individuals with tumors exhibiting high microsatellite instability.

    14. Medical Oncology
      You have free access to this content
      Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma (pages 4958–4965)

      Jonathan Verma, Eric Jonasch, Pamela Allen, Nizar Tannir and Anita Mahajan

      Article first published online: 11 APR 2011 | DOI: 10.1002/cncr.26138

      The use of tyrosine kinase inhibitors has become the mainstay of therapy of high-risk renal cell carcinoma. This study reveals that treatment with these agents reduces the incidence of brain metastasis in high-risk metastatic renal cell cancer.

    15. Pediatric Oncology
      You have free access to this content
      Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma : A report from the Children's Oncology Group (pages 4966–4976)

      Scott C. Borinstein, Donald A. Barkauskas, Mark Krailo, Daniel Scher, Lauren Scher, Silke Schlottmann, Bhaskar Kallakury, Paul S. Dickman, Bruce R. Pawel, Daniel C. West, Richard B. Womer and Jeffrey A. Toretsky

      Article first published online: 8 APR 2011 | DOI: 10.1002/cncr.26112

      The authors investigated the insulin-like growth factor-1 (IGF-1) signaling pathway in patients with newly diagnosed Ewing sarcoma. The baseline IGF-1:IGF binding protein-3 (IGFBP-3) ratio was correlated with age but not with patient outcomes. IGF-1 levels, IGFBP-3 levels, and phosphorylation of downstream signaling targets of IGF-1 pathway activation were not correlated with survival.

    16. You have free access to this content
      Reirradiation for recurrent medulloblastoma (pages 4977–4982)

      Richard L. Bakst, Ira J. Dunkel, Stephen Gilheeney, Yasmin Khakoo, Oren Becher, Mark M. Souweidane and Suzanne L. Wolden

      Article first published online: 14 APR 2011 | DOI: 10.1002/cncr.26148

      Carefully planned reirradiation represents a feasible treatment option in recurrent medulloblastoma with acceptable toxicity. The results in this series are promising and provide the preliminary safety and efficacy data for future study of trimodality therapy.

    17. Psychosocial Oncology
      You have free access to this content
      Sisters Peer Counseling in Reproductive Issues After Treatment (SPIRIT) : A peer counseling program to improve reproductive health among African American breast cancer survivors (pages 4983–4992)

      Leslie R. Schover, Michelle M. Rhodes, George Baum, Jennifer Harned Adams, Rosell Jenkins, Pamela Lewis and Karen Eubanks Jackson

      Article first published online: 14 APR 2011 | DOI: 10.1002/cncr.26139

      African American breast cancer survivors were randomized to receive either a workbook that promoted reproductive health plus up to 30 minutes of telephone counseling or the workbook with 3 sessions of face-to-face peer counseling. Both groups improved by 1-year follow-up in knowledge, distress, and hot flashes.

    18. You have free access to this content
      Feasibility of an expressive-disclosure group intervention for post-treatment colorectal cancer patients : Results of the Healthy Expressions study (pages 4993–5002)

      Cindy L. Carmack, Karen Basen-Engquist, Ying Yuan, Anthony Greisinger, Miguel Rodriguez-Bigas, Robert A. Wolff, Trina Barker, George Baum and James W. Pennebaker

      Article first published online: 8 APR 2011 | DOI: 10.1002/cncr.26110

      The Healthy Expressions program improved psychological functioning in distressed colorectal cancer patients. The program is feasible and should be evaluated in a larger randomized trial.

    19. Symptom Control and Palliative Care
      You have free access to this content
      End-of-life care in Medicare beneficiaries dying with pancreatic cancer (pages 5003–5012)

      Kristin M. Sheffield, Casey A. Boyd, Jamie Benarroch-Gampel, Yong-Fang Kuo, Catherine D. Cooksley and Taylor S. Riall

      Article first published online: 14 APR 2011 | DOI: 10.1002/cncr.26115

      This study examined hospice enrollment and aggressiveness of care for pancreatic cancer patients at the end of life. Although hospice use increased over time, there was a simultaneous increase in aggressive care at the end of life for patients with pancreatic cancer.

    20. Translational Research
      You have free access to this content
      Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy (pages 5013–5020)

      Allan Lipton, Kim Leitzel, Suhail M. Ali, Walter Carney, Greg Platek, Klaudia Steplewski, Ron Westlund, Robert Gagnon, Anne-Marie Martin and Julie Maltzman

      Article first published online: 31 MAR 2011 | DOI: 10.1002/cncr.26101

      Significant decreases in serum human epidermal growth factor receptor 2 (HER2)/neu levels during the first 16 weeks of lapatinib monotherapy were associated with better clinical outcome (longer progression-free survival and increased overall response rate) in HER2-positive metastatic breast cancer patients.

  5. Erratum

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Erratum
    1. You have free access to this content
      Erratum (page 5021)

      Article first published online: 11 APR 2011 | DOI: 10.1002/cncr.26159

SEARCH

SEARCH BY CITATION